Joseph P. Lucia & Associates LLC bought a new position in Pfizer Inc. (NYSE:PFE – Get Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,216 shares of the biopharmaceutical company’s stock, valued at approximately $63,000.
Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Bedel Financial Consulting Inc. boosted its position in Pfizer by 3.5% during the 1st quarter. Bedel Financial Consulting Inc. Now owns 22,800 shares of the biopharmaceutical company’s stock valued at $1,180,000 after purchasing an additional 776 shares during the period. Alhambra Investment Partners LLC boosted its position in Pfizer by 81.5% during the 1st quarter. Alhambra Investment Partners LLC now owns 20,379 shares of the biopharmaceutical company’s stock valued at $1,055,000 after purchasing an additional 9,152 shares during the period. American Trust Investment Advisors LLC boosted its position in Pfizer by 5.1% during the 1st quarter. American Trust Investment Advisors LLC now owns 6,217 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 300 shares during the period. Avity Investment Management Inc. boosted its position in Pfizer by 3.3% during the 1st quarter. Avity Investment Management Inc. Now owns 13,984 shares of the biopharmaceutical company’s stock valued at $724,000 after purchasing an additional 451 shares during the period. Finally, Kwmg LLC boosted its position in Pfizer by 0.4% during the 1st quarter. Kwmg LLC now owns 88,079 shares of the biopharmaceutical company’s stock valued at $4,560,000 after purchasing an additional 310 shares during the period. Institutional investors own 66.50% of the company’s stock.
Shares of Pfizer stock opened at $52.31 on Friday. The stock’s fifty day moving average is $50.66 and its 200-day moving average is $52.15. The firm has a market capitalization of $293.51 billion, a PE ratio of 12.00, a price-to-earnings-growth ratio of 0.63 and a beta of 0.76. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. Pfizer Inc. has a 12-month low of $38.93 and a 12-month high of $61.71.
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. During the same quarter in the prior year, the firm posted $0.93 EPS. The business’s quarterly revenue was up 76.8% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 6.61 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, July 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.06%. Pfizer’s dividend payout ratio is 36.70%.
In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the transaction, the executive vice president now owns 38,146 shares in the company, valued at $1,907,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock worth $2,075,003 in the last quarter. 0.05% of the stock is currently owned by corporate insiders.
Several brokerages have weighed in on PFE. Berenberg Bank set a $50.00 target price on Pfizer in a research note on Friday, May 27th. JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a research note on Tuesday. Morgan Stanley began coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 target price on the stock. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Finally, Citigroup lifted their target price on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.26.
About Pfizer (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.